Wilmington, DE, United States of America

Song Mei

USPTO Granted Patents = 41 (Patent Applications = 19)

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 17 (Patent Applications = 27)

Average Co-Inventor Count = 5.7

ph-index = 14

Forward Citations = 498(Granted Patents)

Company Filing History:

Incyte Holdings Corporation

patents

1 out of 18

Prelude Therapeutics Incorporated

patents

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448389 - BRM targeting compounds and associated methods of use (2025-10-21),

2. 12415809 - Pyrrolotriazine compounds as tam inhibitors (2025-09-16),

3. 12247020 - Bipyrazole derivatives as JAK inhibitors (2025-03-11),

4. 12201636 - Heterocyclylamines as PI3K inhibitors (2025-01-21),

5. 12152033 - Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders (2024-11-26),

6. 12030889 - Imidazopyridazine and imidazopyridine compounds and uses thereof (2024-07-09),

7. 11905275 - Bipyrazole derivatives as JAK inhibitors (2024-02-20),

8. 11851442 - Tricyclic fused thiophene derivatives as JAK inhibitors (2023-12-26),

9. 11819505 - Heterocyclylamines as PI3K inhibitors (2023-11-21),

10. 11780840 - Tricyclic urea compounds as JAK2 V617F inhibitors (2023-10-10),

11. 11767323 - Tricyclic pyridone compounds as JAK2 V617F inhibitors (2023-09-26),

12. 11613536 - Heterocyclic compounds as immunomodulators (2023-03-28),

13. 11591318 - Bipyrazole derivatives as JAK inhibitors (2023-02-28),

14. 11459329 - Imidazopyridazine and imidazopyridine compounds and uses thereof (2022-10-04),

15. 11433071 - Heterocyclylamines as PI3K inhibitors (2022-09-06),

Title: Song Mei: A Pioneer in PI3K Inhibitor Innovations

Introduction

Song Mei, based in Wilmington, DE, is an accomplished inventor with a remarkable portfolio of 38 patents. His work centers around the innovative development of compounds that target specific enzymes, particularly in the context of treating various diseases.

Latest Patents

Among his latest patents, Song Mei has contributed significantly to the field of medicinal chemistry with his invention titled "Heterocyclylamines as PI3K inhibitors." This advanced research presents heterocyclylamine derivatives that are capable of modulating the activity of phosphoinositide 3-kinases (PI3Ks). These compounds are promising in the treatment of diseases linked to PI3K activity, including inflammatory disorders, immune-based disorders, and cancer. Another crucial patent by Mei is "Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders." This patent outlines methods for treating PI3Kδ related disorders, employing specific compounds that can be utilized in therapeutic settings.

Career Highlights

Song Mei has made significant strides in his career while working at renowned organizations such as Incyte Corporation and Incyte Holdings Corporation. His time with these institutions has allowed him to further develop his expertise in the design and application of novel pharmacological compounds.

Collaborations

Throughout his career, Song has collaborated with prominent scientists, including Yun-Long Li and Eddy W Yue. These partnerships have undoubtedly fostered a collaborative environment that enhances innovation and accelerates the development of new therapeutic solutions.

Conclusion

With a substantial number of patents to his name, Song Mei stands out as a key figure in the field of targeted therapy development. His innovative contributions to PI3K inhibitors play a crucial role in addressing some of the most challenging health issues, making a lasting impact on modern medicine.

This text is generated by artificial intelligence and may not be accurate.